Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis-Reference-Cited by-同舟云学术

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

Published:2019-07-15 Issue:10 Volume:49 Page:1147-1161
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Shimozato Naotaka¹,Namisaki Tadashi¹,Kaji Kosuke¹,Kitade Mitsuteru¹,Okura Yasushi¹,Sato Shinya¹,Moriya Kei¹,Seki Kenichiro¹,Kawaratani Hideto¹,Takaya Hiroaki¹,Sawada Yasuhiko¹,Saikawa Soichiro¹,Nakanishi Keisuke¹,Furukawa Masanori¹,Fujinaga Yukihisa¹,Kubo Takuya¹,Asada Kiyoshi¹,Kitagawa Koh¹,Tsuji Yuki¹,Kaya Daisuke¹,Ozutsumi Takahiro¹,Akahane Takemi¹,Mitoro Akira¹,Yoshiji Hitoshi¹

Affiliation:

1. Third Department of Internal MedicineNara Medical University Kashihara Nara Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13385

Reference40 articles.

1. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus

2. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

3. Pathological Findings of NASH and NAFLD